CA Patent

CA2800913A1 — The use of inhibitors of bruton's tyrosine kinase (btk)

Assigned to Pharmacyclics LLC · Expires 2011-12-08 · 14y expired

What this patent protects

The present invention relates to methods for the treatment of cancer comprising: a) administering a Btk kinase inhibitor to a subject sufficient to cause an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b) determining the expr…

USPTO Abstract

The present invention relates to methods for the treatment of cancer comprising: a) administering a Btk kinase inhibitor to a subject sufficient to cause an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b) determining the expression profile of one or more biomarkers from one or more lymphocyte subpopulations; and c) administering a second agent based on the determined expression profile.

Drugs covered by this patent

Patent Metadata

Patent number
CA2800913A1
Jurisdiction
CA
Classification
—
Expires
2011-12-08
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.